Business Wire

ADVA

18.2.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA unveils industry’s most compact 100G edge demarcation solution

ADVA (FSE: ADV) today launched the industry’s most compact demarcation and aggregation technology, bringing cost-effective MEF 3.0-certified 100Gbit/s services to the network edge. The ADVA FSP 150-XG400 Series enables businesses and mobile network operators (MNOs) to easily scale their metro networks and tackle booming bandwidth demand. Specifically engineered to deliver MEF 3.0 Carrier Ethernet 100Gbit/s demarcation and 10Gbit/s service aggregation, the new product family features the market’s only uncompromised line-rate 100Gbit/s activation testing. It also supports hardware-based timing for ultra-precise frequency and phase synchronization, making it the ideal choice for radio access networks. With its high-density and environmentally hardened design, the ADVA FSP 150-XG400 Series is also easy to deploy in space-restrictive locations with no temperature control – a key requirement for the rollout of 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005165/en/

“The arrival of 5G is bringing unprecedented data speeds, but mobile applications can only be as fast as the backhaul network. That’s why MNOs are now looking to upgrade their access infrastructure from 10Gbit/s to 100Gbit/s line rates. Our FSP 150-XG400 Series supports a smooth and extremely cost-effective migration to higher capacity while also enabling the distribution of precise network synchronization that next-generation services require,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “With their compact, ETSI-compliant design, our FSP 150-XG400 devices remove the need for deep shelves and excessive rack height units. This makes it easy and affordable to seamlessly upgrade from 1Gbit/s to 10Gbit/s or even 100Gbit/s service delivery. What’s more, the new solutions feature integrated testing capabilities, so operators don’t have to bother with expensive high-bitrate testing equipment.”

The ADVA FSP 150-XG400 Series of high-density service aggregation solutions is the ultimate tool for scaling edge networks for future wholesale, business, mobile fronthaul and backhaul service needs. Available in a 1RU or 2RU form factor, the unprecedentedly compact and highly versatile product range features 1, 10, 25, 40 or 100GbE interfaces. Each device comes with carrier-class Ethernet OAM and Y.1564 feature sets, including unique full line-speed activation testing for services up to 100Gbit/s. The ADVA FSP 150-XG400 Series supports network overlay capabilities for the delivery of MEF services over IP networks. It also provides standard SDN interfaces and can be directly controlled from open source and commercial SDN controllers. Able to withstand an extended temperature range, the ADVA FSP 150-XG400 Series avoids the high cost of air conditioning, enabling ease of deployment even in extreme environments.

“Our newest product family removes all the roadblocks and makes the task of transforming metro networks simple. With our FSP 150-XG400 Series delivering high-density demarcation and aggregation, businesses can expand and embrace the potential of IoT, and operators can deliver the next level of resilient SLA-based Carrier Ethernet services,” commented James Buchanan, GM, Edge Cloud, ADVA. “No other solution available offers such high port count, full testing capabilities and comprehensive network synchronization features with this level of design density. Our devices also provide proven OAM capabilities as well as fully automated service activation. Whether you need high-speed connectivity for cloud-centric business applications or building your enterprise IoT architecture, our FSP 150-XG400 Series has you covered.”

Watch this video for more information on the FSP 150-XG400 Series: https://youtu.be/bCzD9ffS0N8 .

Further details are also available in these slides: https://adva.li/fsp-150-xg400-series-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye